[
  {
    "ts": null,
    "headline": "Bank On Healthcare And An Aging Population With 14% Yield: HQH",
    "summary": "Discover how rising healthcare spending can be turned into income growth. Build a retirement portfolio that thrives in a key sector.",
    "url": "https://finnhub.io/api/news?id=51e0b31c470fe3a32598b7340dd31af509a06ea732c62173163dd76df69c1d09",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755588900,
      "headline": "Bank On Healthcare And An Aging Population With 14% Yield: HQH",
      "id": 136417379,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195105991/image_2195105991.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Discover how rising healthcare spending can be turned into income growth. Build a retirement portfolio that thrives in a key sector.",
      "url": "https://finnhub.io/api/news?id=51e0b31c470fe3a32598b7340dd31af509a06ea732c62173163dd76df69c1d09"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs Reiterated a Buy Rating on Vertex Pharmaceuticals (VRTX), Kept the PT Unchanged",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 11, Goldman Sachs analyst Salveen Richter reiterated a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a price target of $624. The reiterated bullish sentiment follows the announcement of strong fiscal second-quarter results by the […]",
    "url": "https://finnhub.io/api/news?id=12b2bdf04e1380f1b1f0a49a2659bd6ab06090f7094536ef93312b37bb988f5d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755573344,
      "headline": "Goldman Sachs Reiterated a Buy Rating on Vertex Pharmaceuticals (VRTX), Kept the PT Unchanged",
      "id": 136417156,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 11, Goldman Sachs analyst Salveen Richter reiterated a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a price target of $624. The reiterated bullish sentiment follows the announcement of strong fiscal second-quarter results by the […]",
      "url": "https://finnhub.io/api/news?id=12b2bdf04e1380f1b1f0a49a2659bd6ab06090f7094536ef93312b37bb988f5d"
    }
  }
]